Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.

Reinicke KE, Kuffel MJ, Goetz MP, Ames MM.

Cancer Chemother Pharmacol. 2010 Aug;66(3):575-83. doi: 10.1007/s00280-009-1198-z. Epub 2009 Dec 11.

2.

Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells.

Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA.

Mol Cancer Ther. 2004 Jun;3(6):715-25.

3.

Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2.

Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, Ames MM.

Mol Pharmacol. 2002 Jul;62(1):143-53.

PMID:
12065765
4.

Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells.

McLean L, Soto U, Agama K, Francis J, Jimenez R, Pommier Y, Sowers L, Brantley E.

Int J Cancer. 2008 Apr 1;122(7):1665-74.

5.

The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.

Pledgie-Tracy A, Billam M, Hacker A, Sobolewski MD, Woster PM, Zhang Z, Casero RA, Davidson NE.

Cancer Chemother Pharmacol. 2010 May;65(6):1067-81. doi: 10.1007/s00280-009-1112-8. Epub 2009 Aug 30.

6.

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.

Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK.

J Natl Cancer Inst. 1996 Jun 5;88(11):734-41.

PMID:
8637027
7.
8.

CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines.

Pobst LJ, Ames MM.

Cancer Chemother Pharmacol. 2006 May;57(5):569-76. Epub 2005 Aug 11.

PMID:
16096788
9.
10.
12.

Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.

Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K.

Cancer Res. 2006 Jun 1;66(11):5836-46.

13.

Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells.

Jeansonne DP, Koh GY, Zhang F, Kirk-Ballard H, Wolff L, Liu D, Eilertsen K, Liu Z.

Oncol Rep. 2011 May;25(5):1473-80. doi: 10.3892/or.2011.1187. Epub 2011 Feb 17.

PMID:
21331447
14.

Selective cytotoxicity and combined effects of camptothecin or paclitaxel with sodium-R-alpha lipoate on A549 human non-small cell lung cancer cells.

Ibrahim S, Gao D, Sinko PJ.

Nutr Cancer. 2014;66(3):492-9. doi: 10.1080/01635581.2013.749290. Epub 2013 Sep 24.

15.

Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.

Konecny G, Untch M, Slamon D, Beryt M, Kahlert S, Felber M, Langer E, Lude S, Hepp H, Pegram M.

Breast Cancer Res Treat. 2001 Jun;67(3):223-33.

PMID:
11561768
16.

Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.

Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan MF, Chou TC, Scotto KW, Bertino JR.

Cancer Res. 2002 Dec 1;62(23):6909-15.

17.

The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.

Budman DR.

Cancer Invest. 2002;20 Suppl 2:38-44. Review. No abstract available.

PMID:
12442348
18.

Activation of aminoflavone (NSC 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone gamma-H2AX.

Meng LH, Shankavaram U, Chen C, Agama K, Fu HQ, Gonzalez FJ, Weinstein J, Pommier Y.

Cancer Res. 2006 Oct 1;66(19):9656-64.

19.

Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest.

Jones CB, Clements MK, Wasi S, Daoud SS.

Cancer Chemother Pharmacol. 2000;45(3):252-8.

PMID:
10663644

Supplemental Content

Support Center